Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CDK13 | Q14004 | 3/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561751 | 1.00 | BTK (0.45) | BTKBRD4CREBBPCDK13CDK12 | |
| SCHEMBL25377645 | 1.00 | BTK (0.45) | BTKBRD4CREBBPCDK13CDK12 | |
| SCHEMBL25376670 | 0.95 | BTK (0.44) | BTKBRD4CREBBPCDK13CDK12 | |
| SCHEMBL25259860 | 0.95 | BTK (0.44) | BTKBRD4CREBBPCDK13CDK12 | |
| SCHEMBL25825805 | 0.88 | BTK (0.44) | BTKBRD4CREBBPCDK13CDK12 | |
| SCHEMBL25379224 | 0.86 | BTK (0.47) | BTKCDK13CDK12CDK7JMJD6 | |
| SCHEMBL26196976 | 0.85 | BTK (0.46) | BTKCDK13CDK12CDK7JMJD6 | |
| SCHEMBL25379494 | 0.85 | BTK (0.45) | BTKCREBBPCDK13CDK12CDK7 | |
| SCHEMBL25379448 | 0.84 | BTK (0.44) | BTKCDK13CDK12CDK7JMJD6 | |
| SCHEMBL25256772 | 0.84 | BTK (0.49) | BTKCDK13CDK12CDK7JMJD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | BTK 4058/4885BRD4 143/4885CREBBP 14/4885 |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | BTK 4058/4885BRD4 143/4885CREBBP 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.